Neuronetics (STIM) CFO awarded 25,000 RSUs vesting from 2027

Rhea-AI Filing Summary

Pfanstiel Steven reported acquisition or exercise transactions in this Form 4 filing.

Neuronetics, Inc. reported that EVP, CFO and Treasurer Steven Pfanstiel received an equity grant of 25,000 restricted stock units (RSUs). Each RSU represents a right to receive one share of common stock, vesting in three equal annual installments beginning on March 17, 2027, subject to his continuous service. Following this award, Pfanstiel is shown as holding 845,212 shares of common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfanstiel Steven

(Last) (First) (Middle)

C/O NEURONETICS, INC.

3222 PHOENIXVILLE PIKE

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuronetics, Inc. [ STIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CFO and Treasurer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		A		25,000(1)	A	$0(2)	845,212	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award that vests in three equal annual installments beginning on March 17, 2027, in each case subject to continuous service of the Reporting Person through such date.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

	/s/ Patrick Devine, as Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Neuronetics (STIM) report for Steven Pfanstiel?

Neuronetics reported that EVP, CFO and Treasurer Steven Pfanstiel received an equity grant of 25,000 restricted stock units (RSUs). These awards are part of his compensation and convert into common shares as they vest over time.

How do the new RSUs granted to Neuronetics (STIM) CFO vest?

The 25,000 RSUs granted to Neuronetics CFO Steven Pfanstiel vest in three equal annual installments starting on March 17, 2027. Each installment requires his continuous service through the applicable vesting date to receive the underlying shares.

What does each RSU granted by Neuronetics (STIM) to its CFO represent?

Each RSU granted to the Neuronetics CFO represents a contingent right to receive one share of Neuronetics common stock. The shares are not issued immediately; they are delivered only as the RSUs vest according to the stated schedule.

How many Neuronetics (STIM) shares does the CFO hold after this RSU grant?

After the reported RSU award, Steven Pfanstiel is listed as holding 845,212 shares of Neuronetics common stock directly. This figure reflects his position as of the filing following the 25,000 RSU grant transaction.

Was the Neuronetics (STIM) CFO’s RSU grant an open-market purchase or a compensation award?

The transaction is a compensation-related award, not an open-market purchase. It is coded as a grant or award acquisition at a price of $0.00 per share, reflecting stock-based compensation rather than a cash-funded share purchase.